XOMA Corp at H.C. Wainwright BioConnect Investor Conference Transcript
Good morning, everybody. I think we're still at morning. Yes, we are. Welcome back to H.C. Wainwright's third Annual BioConnect Conference. My name is Joe Pantginis. I'm the Director of Research and Managing Director here at the firm. Pleasure to have with us for our next fireside chat, XOMA. Presenting for the company is Owen Hughes, the Executive Chair; and Brad Sitko, the Chief Investment Officer.
And before we dive in, I'd say, essentially, I have covered every iteration of XOMA, I believe, back when it was a drug development company to what you are now. And I would say that going back several years ago when we had our global conference in Monaco, was one of the first times that Jim Neal, who is now retired, really presented your new strategy of royalty aggregator. And I'd say from between then and now, you've really solidified the thesis. So I give you my own congratulations for that.
Questions & Answers
So I guess, let's just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |